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Postoperative delirium is a common neuropsychiatric syndrome resulting a high postsurgical mortality 
rate and decline in postdischarge function. Extensive research has been performed on both human 
and animal delirium‑like models due to their clinical significance, focusing on systematic inflammation 
and consequent neuroinflammation playing a key role in the pathogenesis of postoperative cognitive 
dysfunctions. Since animal models are widely utilized for pathophysiological study of neuropsychiatric 
disorders, this study aimed at examining the validity of the scopolamine‑induced delirium‑like mice 
model with respect to the neuroinflammatory hypothesis of delirium. Male C57BL/6 mice were 
treated with intraperitoneal scopolamine (2 mg/kg). Neurobehavioral tests were performed to 
evaluate the changes in cognitive functions, including learning and memory, and the level of anxiety 
after surgery or scopolamine treatment. The levels of pro‑inflammatory cytokines (IL‑1β, IL‑18, 
and TNF‑α) and inflammasome components (NLRP3, ASC, and caspase‑1) in different brain regions 
were measured. Gene expression profiles were also examined using whole‑genome RNA sequencing 
analyses to compare gene expression patterns of different mice models. Scopolamine treatment 
showed significant increase in the level of anxiety and impairments in memory and cognitive 
function associated with increased level of pro‑inflammatory cytokines and NLRP3 inflammasome 
components. Genetic analysis confirmed the different expression patterns of genes involved 
in immune response and inflammation and those related with the development of the nervous 
system in both surgery and scopolamine‑induced mice models. The scopolamine‑induced delirium‑
like mice model successfully showed that analogous neuropsychiatric changes coincides with the 
neuroinflammatory hypothesis for pathogenesis of delirium.
Postoperative cognitive dysfunction (POCD) is a common complication of the central nervous system in the 
postoperative period with manifestations such as damage to memory, mental capacity, language ability, or other 
aspects of cerebral  function1 and with an acute phase of cognitive impairment defined as postoperative delirium 
(POD)2. POD shows characteristic clinical features such as inattention, mood changes, and psychiatric  disorders3. 
POCD and POD have been associated with clinically significant adverse outcomes, including prolonged hos-
pitalization, decreased quality of life, and increased postoperative complications and  mortality4,5. As the exact 
mechanism of POCD and POD remains to be explored, the activation of inflammation and immune systems is 
strongly regarded as the key mechanism for cognitive deterioration in postoperative  period6.
Forebrain cholinergic neurons play a fundamental role in controlling the central nervous system with regards 
to attention, memory and cognitive function, and are implicated in cognitive decline and several neurodegenera-
tive  diseases7–9. The impact of cholinergic pathways on the immune system is also well-documented7 showing that 
systemic inflammatory responses are under the control of the cholinergic anti-inflammatory pathway supplied 
by connections of the vagus  nerve7,10. Cholinergic signaling can also control peripheral cytokine production by 
cholinergic anti-inflammatory pathway  activity11. It is reported that alterations in cholinergic system is involved 
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in postoperative delirium in elderly  patients12. In a similar context, experimental and clinical studies focusing on 
the pathogenesis for delirium show that it is accompanied by cholinergic pathways and  agents13,14.
Scopolamine is an anti-cholinergic drug that antagonizes the muscarinic cholinergic receptors (mAChRs) and 
is capable of producing deficits in the processes of learning acquisition, and  consolidation15. Scopolamine-treated 
animal models are widely used in neurocognitive studies because scopolamine administration induces both the 
behavioral and molecular features of Alzheimer’s disease and other neurocognitive disorders, including impaired 
cognition, and imbalanced cholinergic transmission in the hippocampus and prefrontal  cortex16–18. In relation 
with the delirium occurrence, treatment with scopolamine had been conferred a relative risk for postoperative 
delirium in patients undergoing orthopedic  surgery19. Scopolamine patch had also induced scopolamine-induced 
mental disorder especially in the  elderly20.
Despite the highly analogous clinical traits and alterations in cholinergic neurotransmission in scopola-
mine-treated animal  models21, the exact pathogenesis related to inflammatory response of POD still remains 
insufficient. The aim of this study was to validate the effectiveness of scopolamine-treated animal models as 
POD experimental model, by identifying the change in inflammation-related cytokines and inflammasome 
components in various brain regions and candidate genes using RNA sequencing technology by comparing a 
scopolamine-induced delirium-like mice model and surgery mice.
Methods
Animals and ethics statement. Male C57BL/6 mice aged 9–12 weeks (25–28 g) from Orient Bio (Seong-
nam, Gyeonggi-Do, South Korea) were used for the experiment. All in vivo experimental procedures were certi-
fied and approved by the Institutional Animal Care and Use Committee (IACUC) of Yonsei University Health 
System, which is certified by the Association for Assessment and Accreditation of Laboratory Animal Care Inter-
national (AAALAC). All experimental procedures were conducted according to the guide for the care and use 
of laboratory animals (8th edition) by the National Research Council Committee, USA. All mice were housed 
under controlled environment with 12-h light/dark cycles and temperature, and ad  libitum access to chews 
and water in a specific pathogen-free (SPF) facility at the Yonsei Biomedical Research Institute. The present 
experiment was performed according to an approved animal protocol (No. 2016-0335). The study is reported 
in accordance with the ARRIVE guidelines for reporting experiments involving animals (http:// www. nc3rs. org. 
uk/ arrive- guide lines).
Experimental design and procedure. The mice were assigned into four groups using appropriate ran-
domization methods: (1) a sham group (sham) (n = 10, male), (2) a surgery group (surgery) (n = 10, male), (3) 
a vehicle-treated control group (vehicle) (n = 10, male), and (4) a scopolamine-treated group (scopolamine) 
(n = 10, male). Mice in the sham group were kept unaffected to the experimental conditions, while mice in the 
surgery group underwent abdominal surgery. For the scopolamine-treated group, scopolamine (2 mg/kg)21,22 
was dissolved in sterile saline (0.9% NaCl w/v) with the volumes for the administration prepared according 
to the body weight. Mice in the surgery and sham group performed behavioral test at day 4 and 5 postsurgery. 
After behavioral test, mice were sacrificed. Mice in both the vehicle and scopolamine-treated groups performed 
behavioral test at day 1 before scopolamine or vehicle treatment (4th day of the sham and surgery group). At day 
2 (5th day of the sham and surgery group), the mice were injected with scopolamine intraperitoneally 30 min-
utes (min) before the neurobehavioral tests. The same amount of sterile saline was administrated into mice of 
the vehicle group at 30 min before the neurobehavioral tests. After neurobehavioral tests, vehicle or scopolamine 
injected mice were sacrificed at 3 h after injection (Fig. 1A,B). The surgical procedure was as follows. In the 
surgery group, mice were anesthetized with 4% isoflurane and were maintained with 1.5–2% isoflurane in oxy-
gen at a flow rate of 1 L/min. Mice were placed on a heating pad during anesthesia to prevent hypothermia. As 
abdominal surgery is well-established interventional method in developing POCD  model23,24, it was performed 
in surgery group mice as mentioned previously with some modifications in this  study25,26. After incision of the 
peritoneum, superior mesenteric artery was separated and clipped for 20 min to mimic the abdominal surgery 
in mice. Concomitantly, small intestines were exposed and rubbed for 30 seconds (sec) by the operator to mimic 
the actual clinical surgical procedures. The small intestines and exteriorized abdominal muscle and skin were 
placed back into the peritoneal cavity and closed using sutures. Tramadol (20 mg/kg) was administrated intra-
peritoneally to mice undergoing surgery for postoperative analgesia. In sham group, mice were anesthetized fol-
lowing the same method, however the surgical procedure was omitted in this group. Mice were returned to the 
home cage. At day 5 postsurgery or 3 h after scopolamine treatment, mice brains, including the hippocampus, 
prefrontal cortex, and amygdala, were isolated after sacrifice.
Neurobehavioral assessment. The neurobehavioral findings of the mice were assessed using the open 
field test (OFT), elevated plus maze (EPM) and novel object recognition test (NORT). The behavioral tests 
were performed 1 day before drug administration or 4 days after surgery. Mice underwent additional follow-up 
behavioral test 30 min after drug administration or 5 days after surgery according to the treatment plan. All the 
neurobehavioral tests were automatically video recorded and analyzed with an image analyzing system (SMART 
v2.5.21 software and SMART video tracking system, Panlab Harvard Apparatus, Barcelona, Spain) by an asses-
sor blinded to the treatment groups. The mice sequentially performed the OFT, EPM and NORT.
Open field test. Mice were placed in a square open field arena (40 × 40 × 40 cm), were allowed to explore 
for 5 min, and the behaviors were recorded simultaneously. Total distance moved was used as a measure of gen-
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Elevated plus maze. The EPM was performed to evaluate anxiety related behavior, learning, and 
memory functions of the  mice28–30. The maze consisted of two open arms (31 × 6 × 1  cm) and two closed 
arms (31 × 6 × 15 cm) extended from a central platform (5 × 5 × 1 cm), and was elevated to a height of 50 cm 
(JEUNGDO Bio & Plant Co., Ltd.) from the floor. The mice underwent baseline experiments prior to surgery 
or scopolamine treatment, and tested again at day 5 postsurgery or 30 min after scopolamine treatment. Mice 
were individually placed at the end of the open arm facing the other open arm and were allowed to explore for 
5 min. The total duration of time spent in the open and closed arms was recorded respectively. The percentage of 
time spent in the open arms was also measured. The duration of time spent in the open arms also reflects anxi-
ety related  behavior30. The apparatus was cleaned with 70% ethanol prior to all tests. Entry was defined as the 
placement of all paws into the arms of the maze. The ability of learning and memory was calculated as follows: 
Figure 1.  Experimental design and procedure. (A) Scopolamine (2 mg/kg) or vehicle was injected 
intraperitoneally. Mice were subjected to abdominal surgery by clipping superior mesenteric artery and rubbing 
intestines. All mouse brains were isolated, and brain sub-regions, such as hippocampus, prefrontal cortex, and 
amygdala, were analyzed after surgery or scopolamine treatment. (B) Mice in surgery group and sham group 
performed behavioral test at 4 and 5 day post-surgery. Mice in both vehicle and scopolamine-treated groups 
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Transfer latency = the first latency time to enter the closed arms (baseline/training period) – the first latency time 
to enter the closed arms (test period). Transfer latency reflects the changes in learning and memory  function28,29.
Novel object recognition test. NORT was performed to evaluate cognition, especially recognition 
memory in the  mice31. During the habituation phase, each mouse was allowed to explore the square box 
(40 × 40 × 40 cm) freely for 5 min. During the familiarization phase, the mice were placed into the box, which 
contained two identical objects (A + A), and were allowed to explore for 5  min. During the test phase, each 
mouse was returned to the box with the two objects, where one object was changed into a novel object (A + B), 
and mice were allowed to explore for 5 min. During both the familiarization and the test phases, the time spent 
(%) in close-proximity exploration of each object was measured and recorded automatically. At the end of each 
test, the apparatus and the objects were cleaned with 70% ethanol. The habituation phase was performed imme-
diately prior to surgery, the familiarization phase was performed at day 4 postsurgery, and the test trial was 
performed at day 5 postsurgery. The discrimination index was evaluated as: (time taken to explore novel object 
(B)) / (time taken to explore familiar and novel objects (A + B)) × 100, to reflect cognitive ability.
Enzyme‑linked immunosorbent assay (ELISA). For the in vivo cytokine experiment, the hippocam-
pus, prefrontal cortex, and amygdala of mice were obtained at day 5 postsurgery, or at 3 h after scopolamine 
or vehicle treatment after the neurobehavioral tests. Samples were stored at − 80 °C until use. To measure the 
levels of TNF-α, IL-1β, and IL-18 in the three different regions, brains were lysed using tissue protein extrac-
tion reagent (Tissue Protein Extraction Reagent, Thermo Scientific, Waltham, MA, USA) containing protease 
and phosphatase inhibitor cocktail (100 × Halt protease and phosphatase inhibitor cocktail, #1861281 Thermo 
Scientific). The tissues were then homogenized and centrifuged at 13,000 rpm for 10 min to obtain sample super-
natants. Supernatant protein concentrations were measured with a BCA Protein Assay Kit (Thermo Scientific) 
according to the manufacturer’s specifications. Levels of TNF-α, IL-1β, and IL-18 in the lysates were assayed 
using high-sensitivity ELISA kits (R&D Systems Inc., Minneapolis, MN, USA) according to the manufacturer’s 
specifications. Briefly, samples were added to the assay plates at a volume of 50 μL/well and incubated for 2 h at 
room temperature. After washing plates with the wash buffer from the kit, TNF-α, IL-1β, and IL-18 conjugates 
were added to each well and incubated for 2 h. The absorbance of each well was measured at 450 nm using a 
microplate reader. To measure the levels of NLR family pyrin domain-containing protein 3 (NLRP3), apoptosis-
associated speck-like protein containing a C-terminal caspase recruitment domain (ASC), and caspase-1 in 
lysates, ELISA kits from MyBioSource (San Diego, CA, USA) were used for this assay, and all procedures fol-
lowed manufacture’s instruction.
Caspase‑1 activity assay. For measurement of caspase-1 activity, caspase-1 assay kit (Fluorometric) 
(Abcam, Cambridge, UK) was used. It was adopted for detecting caspase-1 activity, which recognizes the 
sequence of YVAD. The hippocampus, prefrontal cortex, and amygdala of mice were obtained at day 5 postsur-
gery, or at 3 h after scopolamine or vehicle treatment. According to manufacturer’s protocol, prepared samples 
were added to 96 well-plate. Then, reaction buffer and YVAD-AFC substrate were added and incubated for 1 h 
at 36 °C. After the reaction, the fluorescence (Ex/Me = 400/505 nm) of each well was measured using FlexStation 
Multi-mode microplate reader.
RNA extraction and gene expression profiling. At day 5 postsurgery or 3 h after scopolamine treat-
ment, mice brains were separated after sacrifice. Total RNA from mouse hippocampus tissue was extracted using 
Trizol reagent (Invitrogen, Carlsbad, CA, USA). RNA quality and quantity were assessed using Agilent 2100 
bioanalyser (Agilent Technologies, USA) and ND-1000 spectrophotometer (NanoDrop Technologies, USA), 
respectively. RNA samples were used as input into the Affymetrix procedure (Affymetrix, Santa Clara, CA, 
USA) as recommended by protocol (http:// www. affym etrix. com), of which total RNA from each sample was 
converted to double-strand cDNA. Amplified RNA (cRNA) was generated from the double-stranded cDNA 
template through an IVT (in vitro transcription) reaction using a random hexamer incorporating a T7 pro-
moter and purified with the Affymetrix sample cleanup module. cDNA was regenerated from a random-primed 
reverse transcription using a dNTP mix containing dUTP. UDG and APE 1 restriction endonucleases were used 
for fragmenting cDNA, which was then end-labelled by terminal transferase reaction incorporating a bioti-
nylated dideoxynucleotide. Fragmented end-labeled cDNA was hybridized to the Affymetrix arrays for 16 h 
(45 ℃ and 60 rpm) as described in the Gene Chip Whole Transcript (WT) Sense Target Labeling Assay Manual 
(Affymetrix). The chips were stained using SAPE (Streptavidin Phycoerythrin), washed in a Genechip Fluidics 
Station 450 (Affymetrix) and scanned using Affymetrix Model 3000 7G scanner. The scanned image data were 
extracted through Affymetrix Command Console 1.1 software to generate raw CEL files, which show expression 
intensity data. Expression data were generated by Transcriptome Analysis Console 4.0.1. For the normalization, 
RMA (Robust Multi-Average) algorithm implemented in Transcriptome Analysis Console software was used.
RNA sequencing analysis of differentially expressed genes. Genes with a more than two-fold dif-
ference in the normalized signals compared to those in control group were selected as differentially expressed 
genes (DEG). Gene ontology analysis of the DEGs was performed by exDEGA (Excel based Differentially 
Expressed Gene Analysis, eBIOGEN, Inc., Seoul, Korea) tool. Categorization of the genes was based on a search 
performed using DAVID v6.8 (http:// david. abcc. ncifc rf. gov). In each group, gene expression level was converted 
to a log2 value, and the relative level with respect to the control group was presented. The clustering heatmap 
profiles of DEGs were compared across the experimental groups using the Multiple Experiment Viewer software 
program v4.9 (MeV). The average fold change (FC) for each gene was expressed as a standardized z-score.
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Statistical analysis. Statistical analyses were performed using GraphPad Prism 7.00 software (GraphPad 
Software, San Diego, CA, USA). Values are presented as mean ± standard error of the mean (SEM). Unpaired 
t-tests were performed to determine statistical significance in behavioral test and caspasae-1 activity. Statisti-
cal comparisons among groups in ELISA and RNA sequencing were assessed with a one-way ANOVA. p val-
ues < 0.05 were considered significant. All graphs are created by using GraphPad Prism 7.00 software (GraphPad 
software) and Fig. 1 image is creased by using Microsoft PowerPoint.
Results
Scopolamine treatment induces delirium‑like cognitive dysfunction in mice. Delirium is related 
to accelerated cognitive  dysfunction2. Therefore, we examined the role and validity of scopolamine treatment 
as the POD model by causing cognitive impairment, similar to POCD caused by the abdominal surgery model. 
Behavioral tests of EPM and NORT were carried out to assess the changes in learning and memory of mice 
after surgery or scopolamine treatment (Fig. 2A–C). In post-behavioral test, during the EPM test, surgery mice 
exhibited significant decrease in transfer latency (sec) as compared to sham group, which indicates POCD. Simi-
larly, scopolamine-treated mice displayed a significant drop in transfer latency with no difference between the 
surgery and scopolamine groups (Fig. 2A), as compared to mice from the vehicle group. To examine the changes 
in learning and memory of mice after surgery or scopolamine treatment, post-behavioral tests were perform 
using the NORT to confirm the changes in learning and memory. The duration of time spent exploring the novel 
object (calculated in percentage using the given formula) significantly decreased in the surgery and scopola-
mine-treated groups, emphasizing the effect of surgery and scopolamine treatment on the impairment of cogni-
tive ability (Fig. 2B). The discrimination index also showed reduced learning and memory ability in surgery or 
scopolamine treatment compared to each control (Fig. 2C). The SMART video tracking system showed real-time 
tracking of each groups in NORT (Supplementary Fig. 1A). Conclusively, neurobehavioral tests indicated that 
Figure 2.  Effects of scopolamine on memory dysfunction and psychological behaviors in post-behavioral tests. 
(A) Changes in learning and memory is presented as the transfer latency (sec) in EPM, (B) the exploration time 
of novel object in NORT after surgery or scopolamine treatment, and (C) discrimination index in NORT after 
surgery or scopolamine treatment. (D) Reduced percentage time in open arms after surgery or scopolamine 
treatment in EPM. (E) Increased total distance travelled in OFT after surgery or scopolamine treatment. (F) 
Lower distance travelled in center zone of OFT after surgery or scopolamine treatment. Values are presented as 
mean ± SEM (n = 4–5). p values < 0.05 were considered significant (*p < 0.05, **p < 0.01, ***p < 0.001 vs. control 
(sham or vehicle), #p < 0.05, ##p < 0.01, ###p < 0.001 vs. surgery). EPM; elevated plus maze, NORT; novel object 
recognition test, EPM; elevated plus maze, OFT; open field test.
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scopolamine treatment significantly caused memory impairments and decrease in cognition in mice, similar to 
the results seen in mice of the surgery group.
Scopolamine treatment promotes delirium‑like anxiety and hyper‑activation in mice. We 
measured the level of anxiety to investigate whether scopolamine administration could lead to psychological dis-
turbance, a characteristic trait of delirium. Mice behavior tests were conducted using EPM and OFT (Fig. 2D–F). 
In post-behavioral test, mice exhibiting the state of anxiety are known to display a tendency of staying in the 
closed arms of the EPM, thus, scopolamine-treated mice spent significantly less amount of time in the open 
arms as compared to mice from the vehicle and surgery groups, and surgery mice also showed less time in open 
arms, as compared to those in the sham group (Fig. 2D). In post-behavioral test, in OFT, there was no signifi-
cant difference between the total distance travelled by the sham and surgery group mice, However, mice in the 
scopolamine-treated group exhibited hyperactive motor activity resulting in significantly greater total distance 
travelled, as compared to mice in the surgery group (Fig. 2E). Additionally, scopolamine-treated mice showed 
lesser distance travelled in the central zone of the OFT (Fig. 2F), suggesting the increased level of anxiety. The 
SMART video tracking system showed visual tracking of each group in EPM and OFT (Supplementary Fig. 1B 
and C).
Transcriptome analysis shows scopolamine treatment alters gene expression pattern in the 
hippocampus. To investigate whether surgery or scopolamine treatment affects the gene expression pattern 
in animal models, we used RNA sequencing analysis to compare the gene expression of hippocampal samples 
from the vehicle, surgery, and scopolamine-treated mice. The heat map showed the two-way hierarchical clus-
tering comparing the gene expression levels among different groups: surgery or scopolamine (Fig. 3A). Dock8, 
Myo1f., Treml2, Gas5, and Ralbp1, were upregulated or downregulated after surgery or scopolamine treatment. 
The normalized repeatability coefficient (RC) of Dhx58, which is involved in process of the immune system, was 
upregulated in both the surgery and scopolamine-treated groups, as compared to the control group. The gene 
expression levels of Dock8, Myo1f., and Treml2 were downregulated in both the surgery and scopolamine-treated 
groups. In the case of Gas5, only the surgery group showed downregulated level, as compared to the control. 
Compared to the surgery group, the level of Ralbp1 was downregulated in both the vehicle and scopolamine-
treated groups (Fig. 3B). In addition, genes involving hippocampal function and the nervous system, such as 
Lrrn4, S100a10, Slc5a7, and Wnt6 were altered by surgery or scopolamine treatment. Gene expression of Lrrn4 
and S100a10 was upregulated, while that of Slc5a7 was downregulated in both the surgery and scopolamine-
treated groups, as compared to the vehicle group. However, only the scopolamine-treated group showed effi-
ciently downregulated expression of Wnt6, as compared to the vehicle and surgery groups (Fig. 3C).
Scopolamine treatment increases pro‑inflammatory cytokines and inflammasome compo‑
nents in the brain. Based on the changes of inflammatory genes in RNA sequencing analysis, the levels of 
pro-inflammatory cytokines were measured from the hippocampal samples using ELISA to compare the effects 
of surgery (day 5 postsurgery) and scopolamine (3  h after injection) on the inflammatory reaction (Fig.  4). 
Both surgery and scopolamine-treated mice showed significantly increased level of pro-inflammatory cytokines 
(TNF-α, IL-1β, and IL-18) (Fig. 4A–C). The levels of pro-inflammatory cytokines IL-1β and IL-18 are regulated 
by inflammasome. Therefore, we measured protein levels of inflammasome components in the hippocampus. 
The expression level of NLRP3 inflammasome components such as NLRP3, ASC, and caspase-1 in the hip-
pocampus were significantly upregulated in both the surgery and scopolamine-treated groups, as compared to 
the vehicle group (Fig. 4D–F). The prefrontal cortex and amygdala are engaged in emotional response and mood 
regulation, such as anxiety and  depression32. We further checked the levels of pro-inflammatory cytokines and 
NLRP3 inflammasome components in the prefrontal cortex and amygdala. Compared to the vehicle group, 
levels of pro-inflammatory cytokines, such as TNF-α, IL-1β, and IL-18, were remarkably higher in the surgery 
group. Additionally, mice of the scopolamine-treated group showed increased levels of TNF-α, IL-1β, and IL-18; 
although, IL-1β and IL-18 protein levels in scopolamine-treated mice were significantly reduced as compared to 
those in the surgery group (Fig. 4A–C). The levels of NLRP3 inflammasome components, such as NLRP3, ASC, 
and caspase-1, were highly expressed in the prefrontal cortex and amygdala in the surgery group. Similar to the 
surgery group, the scopolamine-treated group showed increased levels of NLRP3 inflammasome components in 
the prefronal cortex. Furthermore, the levels of NLRP3 in the amygdala were different between the mice in the 
surgery and scopolamine-treated groups with no incremental changes in the latter. However, ASC and caspase-1 
expressions were higher in the scopolamine-treated group (Fig. 4D–F).
Scopolamine treatment induces inflammasome complex‑induced caspase‑1 activation. The 
degree of caspase-1 activity was measured in the hippocampus, prefrontal cortex, and amygdala at day 5 post-
surgery or 3 h after scopolamine injection (Fig. 5). In Fig. 5A, surgery and scopolamine group showed increased 
levels of caspase-1 activation, compared to each control in the hippocampus. In the prefrontal cortex, only 
scopolamine group showed increased caspase-1 activity, compared to the vehicle group. However, no signifi-
cant differences were seen between the sham and surgery groups (Fig. 5B). In the amygdala, mice in surgery 
group displayed increased caspase-1 activity, compared to the sham group, while scopolamine-treated mice also 
showed increased levels of caspase-1 activation, compared to the vehicle group (Fig. 5C).
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Figure 3.  RNA sequencing transcriptome analysis. (A) Hierarchical clustering of hippocampal samples from 
vehicle, surgery, and scopolamine-treated groups. Samples were clustered according to the gene expression 
profiles of differentially expressed genes between control, surgery, and scopolamine-treated mice, respectively. 
The clustering tree is shown on the left, and the sample clustering tree appears at the top. The color scale shown 
at the top indicates the relative gene expression levels, with red representing a high expression level and blue, a 
low expression level. (B) Differentially expressed mRNAs involving immune/inflammatory response, and (C) 
hippocampal functionality and nervous system after surgery or scopolamine treatment. Values are presented as 
mean ± SEM (n = 2–3). p values < 0.05 were considered significant (*p < 0.05, **p < 0.01, ***p < 0.001 vs control 
(sham or vehicle), ###p < 0.001 vs surgery).
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Discussion
In the present study, scopolamine-treated animals showed characteristic delirium-like behavioral patterns, 
biochemical findings coherent with neuroinflammatory changes, and the activation of inflammasome. RNA 
sequencing profiles also showed consistent changes in gene expression patterns relevant to immune/inflamma-
tory reaction and the nervous system development in both surgery and scopolamine-treated groups, though 
there are some discrepancies in the expression patterns of inflammation-related genes. These results suggest the 
compatibility of scopolamine-treated delirium-like animal model in re-enacting the clinical features of POD, 
although there could still be undisclosed pathophysiology and insufficient explanation for neuroinflammatory-
related POD.
The cholinergic neurotransmitter system is responsible for the control of cognitive processes, acquisition, and 
retention of information as well as task performances. Numerous studies have reported the role of cholinergic 
function in age-related memory dysfunction and other neurocognitive  diseases33,34. Scopolamine is known to 
reproduce delirium-like state in both human and experimental  animals35–37 by inducing dysregulation of cho-
linergic signals in the brain; such cognitive declining properties of scopolamine have contributed to its wide 
application in neurocognitive research.
Oxidative stress has also been proposed as the possible cause for neurocognitive disease along with the 
cholinergic hypothesis. Regarding to the use of scopolamine, previous studies have reported the association of 
Figure 4.  The levels of pro-inflammatory cytokines and NLRP3 inflammasome components in the brain 
regions. (A–C) Increased levels of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-18 in the 
hippocampus, prefrontal cortex and amygdala with surgery or scopolamine treatment. (D–F) Upregulated levels 
of NLRP3, ASC, ad caspase-1 in the hippocampus and prefrontal cortex with surgery or scopolamine treatment. 
Also, increased levels of ASC, ad caspase-1 in the amygdala with surgery or scopolamine treatment except 
NLRP3. Values are presented as mean ± SEM (n = 4–6). p values < 0.05 were considered significant (*p < 0.05, 
**p < 0.01, ***p < 0.001 vs control (sham or vehicle), #p < 0.05, ##p < 0.01, ###p < 0.001 vs surgery).
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systemic administration of scopolamine with increased oxidative stress in the brain, especially the areas associ-
ated with memory and learning, such as the hippocampus and prefrontal  cortex16,38. Although dysregulation of 
the cholinergic system and oxidative stress have been the promising hypothesis for explaining the pathogenesis 
of POCD and delirium, increased inflammation still plays an important part in explaining the development 
of neurocognitive disorders, of which increased level of pro-inflammatory cytokines, such as TNF-α IL-1β, 
IL-18, and IL-6, can be observed in the brain and blood samples of patients with dementia, delirium, and 
 POCD39–41. Scopolamine administration has also been shown to cause increase in pro-inflammatory cytokines, 
and inflammation has been proposed as the theoretical basis for scopolamine-induced memory  impairment16,42. 
The significance of neuroinflammation in delirium is consistent with our results in showing the increase of pro-
inflammatory cytokines in both the surgery and scopolamine-treated groups.
NLRP3 inflammasome, an intracellular sensor that detects a broad range of microbial motifs, has been dem-
onstrated to increase the level of pro-inflammatory cytokines such as IL-1β and IL-18 in the brain by activating 
caspase-143. NLRP3 inflammasome further promotes the aggregation of innate immune cells and initiates the 
downstream inflammatory cascade that ultimately accelerates the pathological progression of neurocognitive 
 disease43–45. Its activation had been the marker for host immune defense mechanism in various inflammatory 
diseases with no exceptions to the development of neurodegenerative disorders. In this study, the activation of 
NLRP3 inflammasome and caspase-1 was observed in three different brain regions, of which the hippocampal 
area of scopolamine-treated mice showed increased activation. Increased activation of NLRP3 inflammasome 
was also seen in the hippocampus of surgery mice implying POCD. Therefore, NLRP3 inflammasome may be 
the main cause of cognitive impairment after surgery as well as scopolamine treatment.
Amygdala is the brain region crucial for executive function, memory, attention, and especially for the patho-
genesis of delirium, along with the frontal lobes, diencephalon and  hippocampus37,46. In addition, the dys-
regulated prefrontal cortex-to-amygdala pathway is associated with  anxiety32. Previous studies have shown the 
significant diminution of neurotransmitters, including dopamine, 3,4-dihydroxy-phenylacetic acid (DOPAC), 
homovanillic acid (HVA), and acetylcholine, in the amygdala of scopolamine-treated animals as compared 
to control group animals, and also compared to the hippocampus area within the same scopolamine-treated 
 groups37,46. In addition, evidences have also suggested altered neurotransmission especially in the regions related 
to memory, such as the hippocampus and amygdala, in relation to outcomes seen in POD. The significance of 
inflammasome is very important in the neuroinflammatory-based hypothesis for POD. In the present study, the 
levels of NLRP3 inflammasome components and caspase-1 activity were all higher in the prefrontal cortical area 
of scopolamine-treated mice; however, the levels of expression were different in the amygdala, showing increase 
in the levels of inflammasome components and caspase-1 activity after scopolamine treatment, but not that of 
NLRP3. Detailed explanation for transition aspects of NLRP3 inflammasome in the amygdala could be limited 
due to restricted information focusing on the direct changes of inflammasome components in the amygdala, of 
which reduced expression of NLRP3 inflammasome can only be indirectly inferred from altered or abnormal 
expression of neurotransmitters. Also, other kinds of inflammasome complexes (e.g. NLRP2, NLRC4, and AIM2) 
might be involved in caspase-1 activation and inflammatory responses in the amygdala. However, in present 
study, we performed ELISA test for inflammatory cytokines except sham group, because there were no differ-
ences between the vehicle and sham groups in post-behavioral tests.
RNA sequencing analysis technique has been widely used for various human disease, and a large amount of 
genetic data has been produced over the past decades from various diseases. With the help of RNA sequencing 
analysis from different treatment groups, this study successfully identified the altered gene expression pat-
terns from each group to further investigate the reliability of scopolamine-treated animal models as compatible 
delirium-like model from neuroinflammatory point of view. We have selected hippocampus as it is the specific 
brain region critical for learning and memory process, and known to have significant association with the 
neuropsychiatric behavioral changes by various studies. Other previous studies had also extracted RNA from 
Figure 5.  The levels of caspase-1 activity in the brain regions. (A) Highly activated level of caspase-1 after 
surgery (day 5 postsurgery) and scopolamine (3 h after injection) in the hippocampus. (B) Increased caspase-1 
activation in the prefrontal cortex after scopolamine treatment. (C) Increased levels of caspase-1 activity in the 
amygdala in surgery and scopolamine groups. Values are presented as mean ± SEM (n = 5). p values < 0.05 were 
considered significant (*p < 0.05, **p < 0.01, ***p < 0.001 vs. control (sham or vehicle)).
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hippocampal tissue to examine the RNA changes in neurobehavioral insults and changes in cognition and 
 memory47,48. After scopolamine treatment, mice showed decreased expression patterns of cholinergic genes 
(Chrnb3, Chrnb4, Chat, Camk2b, Slc18a3, Chrm1) compared to the vehicle, although statistical significances 
were lacking. However, scopolamine treatment significantly reduced the expression levels of cholinergic genes 
(Chrna3, Slc5a7, Slc38a5) compared to the vehicle. This study also identified the genes with significant expression 
profiles related to inflammation and the development of the nervous system that presented with a more distinct 
expression pattern in surgery mice as compared with scopolamine- treated mice (Table 1). For example, gene 
expression of Ralbp1, which was significantly upregulated in surgery mice compared to mice in sham group 
and downregulated in scopolamine-treated mice compared to surgery mice, plays a role in receptor-mediated 
endocytosis and is a downstream effector of the small GTP-binding protein  RAL49. Ralbp1 is known for its 
oncogenic role and necessary role in cell proliferation and invasion in  carcinogenesis50, and it is also known for 
regulating obesity-promoting pro-inflammatory  cytokines51. Gene expression patterns from both the surgery 
and scopolamine-treated groups showed that a number of notable genes were associated with the analogous 
cellular functions, mostly focusing on inflammatory reactions and the development of the neuronal system, 
although expression levels and significance vary to some extent. For example, Dhx58 coding LGP2, is related 
to the regulation of innate immune response, immune system, and apoptosis during viral  infection52. Myo1f. 
encodes myosin-1F protein and is expressed mainly in the immune  system53. It is involved in the regulation of 
M1-polarization during the inflammatory process, whereas Myo1f. deficiency is known to attenuate the com-
mitment of macrophages into a pro-inflammatory phenotype. Myo1f. deficiency model strongly reduces the 
secretion of pro-inflammatory cytokines, decreases epithelial damage, ameliorates disease activity, and enhances 
tissue  repair54,55. Treml2 is a transmembrane protein family, which expresses in various immune cells, such as 
monocytes, macrophage, and microglia. Treml2 is involved in innate and adaptive immunity and causes increase 
in number of macrophages under inflammatory  condition56.
Another gene, Lrrn4, which was upregulated in both the surgery and scopolamine-treated groups, is a protein 
coding gene playing a crucial role in hippocampus-dependent long lasting  memory57. S100a10 encodes a member 
of the S100 family of protein containing 2 EF-hand calcium-binding motifs called S100A10 or p11, which are 
involved in the regulation of various cellular processes such as cell cycle progression and differentiation. Upregu-
lated levels of S100a10 in the hippocampus engage in processing emotional memory and altered hippocampal 
 functionality58, which is due to the interaction of p11 with serotonin-signaling proteins. Moreover, as cognitive 
impairments are common in delirium due to dysfunctional serotonin neurotransmission, p11 protein is known 
to interact with serotonin-signaling proteins and correlate with symptoms of mood  disorders58,59. Scl5a7 is 
implicated in the delivery of the precursor choline from the synaptic space into presynaptic terminal, which is 
Table 1.  Differentially expressed genes in surgery and scopolamine-treated mice. RNA sequencing data 
show several genes related to inflammation and the development of the nervous system in surgery mice and 
scopolamine- treated mice.
Surgery Scopolamine
Gene description GO biological process (gene function)FC p value FC p value
Inflammation/immune response
Dhx58 1.516 0.003 1.488 0.020 DEXH (Asp-Glu-His) box polypeptide 58 Immune system processRegulation of Innate immune response
Dock8 0.559 0.016 0.612 0.044 Dedicator of cytokinesis 8Inflammation
Protein binding
Immunological synapse formation
Myo1f. 0.740 0.017 0.767 0.023 Myosin 1FRegulator of anti-inflammation
ATP, acting binding
Defense response to Gram(+) bacterium
Gas5 0.797 0.032 0.754 0.045 Growth arrest specific 5Molecular function Response to bacterium
Treml2 0.752 0.003 0.762 0.019
Triggering receptor expressed on myeloid 
cells-like 2
Regulation of innate immune response
Ralbp1 1.999 < 0.001 0.945 0.024
ralA binding protein 1
Promotion of pro-inflammatory cytokine 
(in obesity)
ATPase activity/protein binding
Positive regulation of GTPase activity
Signal transduction
Hippocampal functionality/nervous system
Lrrn4 1.482 0.010 1.526 0.008





S100a10 1.518 0.028 1.677 0.004





Positive regulation of GTPase activity
Slc5a7 0.675 0.017 0.723 0.045
Solute carrier family 5 (choline trans-
porter), member 7
Hippocampus




Wnt6 0.818 0.098 0.729 < 0.001 Wingless-type MMTV integration site fam-ily, member 6
Protein/signaling receptor binding
Neuron differentiation
Positive regulation of gene expression
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important in cholinergic neuronal  communication60. To summarize, scopolamine administration can successfully 
reproduce characteristic neuropsychiatric behavioral changes of delirium in accordance with neuroinflamma-
tory hypothesis, although less consistency was noted in descriptive RNA sequencing analysis studies. In this 
study, we have only suggested candidate genes involved in scopolamine-treatment delirium. Therefore, further 
studies focusing on delirium and the involvement of candidate genes for pathophysiological studies are needed.
Delirium represents the large spectrum of cognitive and behavioral abnormalities from hypoactive form, 
with negative symptoms of inattention and flat affect, to hyperactive form with characteristic agitation and 
 anxiousness61. In this study, neurobehavioral tests showed significant increase in the level of anxiety and hyper 
motor activity, and impairment in memory and cognitive function in scopolamine-treated group; this seems 
to be associated with increased level of inflammatory response. Scopolamine is particularly known to damage 
learning and short-term memory functions in rodents and humans by disrupting cholinergic  transmission16, 
which makes it the most widely used drug for reproducing delirium in animal. Therefore, scopolamine treatment 
model has its advantage over other models (Especially a single IP injection of scopolamine) as suitable for POD 
study, while abdominal surgery in animal may be the proper and widely adopted method in developing POCD 
as supported by the previous  studies23,24, but lacks the definite explanation for POD development.
In conclusion, our results show that scopolamine-induced POD animal models had succeeded in showing the 
analogous neurobehavioral patterns, and thus, present findings coherent with neuroinflammatory reactions in 
POD. However, genetic analysis showed the limitations as an indispensable explanation between candidate genes 
and delirium. Undeniably, further studies addressing the possible interactions between delirium and candidate 
genes after scopolamine treatment for pathophysiological studies are necessary.
Data availability
All data supporting the conclusions of this manuscript are provided in the text and figures.
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